<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02561702</url>
  </required_header>
  <id_info>
    <org_study_id>RSRB00057653</org_study_id>
    <nct_id>NCT02561702</nct_id>
  </id_info>
  <brief_title>Mexiletine for Muscle Cramps in Charcot Marie Tooth Disease</brief_title>
  <official_title>Mexiletine for Muscle Cramps in Charcot Marie Tooth Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Charcot Marie Tooth Disease is a family of inherited peripheral neuropathies, with over 70
      causative genes identified to date.1-4 Muscle cramps are frequent in CMT, affecting up to 85%
      of patients with some subtypes of CMT. These cramps impact quality of life and have been
      identified as an important therapeutic target for clinical trials in CMT.1-4 There is no FDA
      approved treatment for muscle cramps.5 Mexiletine is a sodium channel blocker approved for
      treatment of arrhythmias. As a sodium channel blocker, mexiletine offers the promise of
      effective therapy for muscle cramps.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will provide data on the short term efficacy of oral mexiletine in helping to
      prevent muscle cramps in adults with CMT. The study will also assess the short-term safety
      and tolerability of low dose mexiletine in adults with CMT.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">December 31, 2016</completion_date>
  <primary_completion_date type="Actual">December 31, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With a Decrease in Cramp Duration</measure>
    <time_frame>120 minutes</time_frame>
    <description>Participant will be evaluated for muscle cramps 120 minutes following a single dose of oral mexiletine. The Clinical Evaluator applied pressure to provoke hamstring cramps bilaterally, one at a time 2 hours after dose. The cramp duration in seconds of the right hamstring was used.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With a Decrease in Cramp Intensity</measure>
    <time_frame>120 minutes</time_frame>
    <description>Participant will be evaluated for muscle cramps 120 minutes following a single dose of oral mexiletine. The Clinical Evaluator applied pressure to provoke hamstring cramps bilaterally, one at a time 2 hours after dose. The cramp intensity of the right hamstring was reported by the subject on a scale of 1-10 with 1 being weak and 10 being severe.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Charcot Marie Tooth Disease</condition>
  <arm_group>
    <arm_group_label>Mexiletine first/placebo second</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 150 mg of mexiletine by mouth 3 times daily for 5-7 days followed by 7 day washout period and 5-7 days of placebo (240 mg of lactose powder) taken by mouth 3 times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo first/mexiletine second</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive placebo (240 mg of lactose powder) taken by mouth 3 times daily for 5-7 days followed by 7 day washout period and 5-7 days of 150 mg of mexiletine by mouth 3 times daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>240 mg lactose powder in a size 3 capsule taken by mouth 3 times daily for 5-7 days</description>
    <arm_group_label>Mexiletine first/placebo second</arm_group_label>
    <arm_group_label>placebo first/mexiletine second</arm_group_label>
    <other_name>lactose powder</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mexiletine</intervention_name>
    <description>150 mg Mexiletine taken by mouth in capsule form 3 times daily for 5-7 days</description>
    <arm_group_label>Mexiletine first/placebo second</arm_group_label>
    <arm_group_label>placebo first/mexiletine second</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject has known CMT, previously diagnosed by a neurologist with subspeciality
             expertise in neuromuscular disorders/peripheral neuropathy. The diagnosis of CMT
             relies on a combination of clinical history (including family history), neurological
             examination electrophysiological features, and prior genetic testing results.

               -  The subject is at least 18 years old, and has signed the Informed Consent Form.

               -  The subject is ambulatory (cane, walker, orthoses allowed).

               -  The subject has experienced muscle cramps and has known provokable hamstring or
                  calf muscle cramps on MVC.

               -  The subject has a reliable method of birth control (if a female subject of child
                  bearing potential). Reliable birth control is defined as Hormonal contraception
                  Intrauterine contraception/device Any two barrier methods (combination of male or
                  female condom with diaphragm sponge or cervical cap) together with spermicidal
                  foam/gel/film/cream/suppository True abstinence

        Exclusion Criteria:

          -  The subject has a known neuropathy from another source (e.g., diabetes, drug induced,
             alcohol, etc.).

               -  The subject has an untreated medical disorder known to predispose to muscle
                  cramps

               -  The subject is pregnant or nursing, has a known mexiletine allergy or has taken
                  mexiletine in the past 12 weeks.

               -  The subject is participating in another therapeutic trial.

               -  The subject has second or 3rd degree heart block, atrial flutter/fibrillation,
                  ventricular arrhythmias, or is receiving treatment of a cardiac arrhythmia.

               -  The subject is currently taking another agent for muscle cramps or a muscle
                  relaxant (e.g., benzodiazepine, baclofen, tizanidine, soma, meprobromate).

               -  The subject is on another sodium channel blocker or medication that precludes
                  administration of mexiletine.

               -  The subject has known diabetes mellitus, liver or kidney disease requiring
                  ongoing treatment, untreated thyroid dysfunction, symptomatic cardiomyopathy, or
                  symptomatic coronary artery disease.

               -  The subject, in the opinion of the investigator, is unsuitable for enrollment for
                  any other reason
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Herrmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2015</study_first_submitted>
  <study_first_submitted_qc>September 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2015</study_first_posted>
  <results_first_submitted>January 25, 2018</results_first_submitted>
  <results_first_submitted_qc>February 23, 2018</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 26, 2018</results_first_posted>
  <last_update_submitted>February 23, 2018</last_update_submitted>
  <last_update_submitted_qc>February 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>David Herrmann</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tooth Diseases</mesh_term>
    <mesh_term>Charcot-Marie-Tooth Disease</mesh_term>
    <mesh_term>Nerve Compression Syndromes</mesh_term>
    <mesh_term>Hereditary Sensory and Motor Neuropathy</mesh_term>
    <mesh_term>Muscle Cramp</mesh_term>
    <mesh_term>Spasm</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mexiletine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Mexiletine First/Placebo Second</title>
          <description>Participants will receive 150 mg of mexiletine by mouth 3 times daily for 5-7 days followed by 7 day washout period and 5-7 days of placebo (240 mg of lactose powder) taken by mouth 3 times daily
Placebo: 240 mg lactose powder in a size 3 capsule taken by mouth 3 times daily for 5-7 days
Mexiletine: 150 mg Mexiletine taken by mouth in capsule form 3 times daily for 5-7 days</description>
        </group>
        <group group_id="P2">
          <title>Placebo First/Mexiletine Second</title>
          <description>Participants will receive placebo (240 mg of lactose powder) taken by mouth 3 times daily for 5-7 days followed by 7 day washout period and 5-7 days of 150 mg of mexiletine by mouth 3 times daily
Placebo: 240 mg lactose powder in a size 3 capsule taken by mouth 3 times daily for 5-7 days
Mexiletine: 150 mg Mexiletine taken by mouth in capsule form 3 times daily for 5-7 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a Decrease in Cramp Duration</title>
        <description>Participant will be evaluated for muscle cramps 120 minutes following a single dose of oral mexiletine. The Clinical Evaluator applied pressure to provoke hamstring cramps bilaterally, one at a time 2 hours after dose. The cramp duration in seconds of the right hamstring was used.</description>
        <time_frame>120 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mexiletine</title>
            <description>Participants will receive 150 mg of mexiletine by mouth 3 times daily for 5-7 days followed by 7 day washout period and 5-7 days of placebo (240 mg of lactose powder) taken by mouth 3 times daily
Placebo: 240 mg lactose powder in a size 3 capsule taken by mouth 3 times daily for 5-7 days
Mexiletine: 150 mg Mexiletine taken by mouth in capsule form 3 times daily for 5-7 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will receive placebo (240 mg of lactose powder) taken by mouth 3 times daily for 5-7 days followed by 7 day washout period and 5-7 days of 150 mg of mexiletine by mouth 3 times daily
Placebo: 240 mg lactose powder in a size 3 capsule taken by mouth 3 times daily for 5-7 days
Mexiletine: 150 mg Mexiletine taken by mouth in capsule form 3 times daily for 5-7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Decrease in Cramp Duration</title>
          <description>Participant will be evaluated for muscle cramps 120 minutes following a single dose of oral mexiletine. The Clinical Evaluator applied pressure to provoke hamstring cramps bilaterally, one at a time 2 hours after dose. The cramp duration in seconds of the right hamstring was used.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a Decrease in Cramp Intensity</title>
        <description>Participant will be evaluated for muscle cramps 120 minutes following a single dose of oral mexiletine. The Clinical Evaluator applied pressure to provoke hamstring cramps bilaterally, one at a time 2 hours after dose. The cramp intensity of the right hamstring was reported by the subject on a scale of 1-10 with 1 being weak and 10 being severe.</description>
        <time_frame>120 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mexiletine</title>
            <description>Participants will receive 150 mg of mexiletine by mouth 3 times daily for 5-7 days followed by 7 day washout period and 5-7 days of placebo (240 mg of lactose powder) taken by mouth 3 times daily
Placebo: 240 mg lactose powder in a size 3 capsule taken by mouth 3 times daily for 5-7 days
Mexiletine: 150 mg Mexiletine taken by mouth in capsule form 3 times daily for 5-7 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will receive placebo (240 mg of lactose powder) taken by mouth 3 times daily for 5-7 days followed by 7 day washout period and 5-7 days of 150 mg of mexiletine by mouth 3 times daily
Placebo: 240 mg lactose powder in a size 3 capsule taken by mouth 3 times daily for 5-7 days
Mexiletine: 150 mg Mexiletine taken by mouth in capsule form 3 times daily for 5-7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Decrease in Cramp Intensity</title>
          <description>Participant will be evaluated for muscle cramps 120 minutes following a single dose of oral mexiletine. The Clinical Evaluator applied pressure to provoke hamstring cramps bilaterally, one at a time 2 hours after dose. The cramp intensity of the right hamstring was reported by the subject on a scale of 1-10 with 1 being weak and 10 being severe.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Mexiletine</title>
          <description>Participants will receive 150 mg of mexiletine by mouth 3 times daily for 5-7 days followed by 7 day washout period and 5-7 days of placebo (240 mg of lactose powder) taken by mouth 3 times daily
Placebo: 240 mg lactose powder in a size 3 capsule taken by mouth 3 times daily for 5-7 days
Mexiletine: 150 mg Mexiletine taken by mouth in capsule form 3 times daily for 5-7 days</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants will receive placebo (240 mg of lactose powder) taken by mouth 3 times daily for 5-7 days followed by 7 day washout period and 5-7 days of 150 mg of mexiletine by mouth 3 times daily
Placebo: 240 mg lactose powder in a size 3 capsule taken by mouth 3 times daily for 5-7 days
Mexiletine: 150 mg Mexiletine taken by mouth in capsule form 3 times daily for 5-7 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Herrmann</name_or_title>
      <organization>University of Rochester</organization>
      <phone>585-275-4568</phone>
      <email>david_herrmann@urmc.rochester.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

